Literature DB >> 9163594

Treatment of dyskeratosis congenita with granulocyte colony-stimulating factor and erythropoietin.

B P Alter1, F H Gardner, R E Hall.   

Abstract

Aplastic anaemia is both frequent and difficult to manage in patients with dyskeratosis congenita (DC). We recently treated a 23-year-old male for a year with granulocyte colony-stimulating factor (G-CSF) and erythropoietin (Ep), with an excellent neutrophil response, and a transient effect on haemoglobin levels. G-CSF alone or combined with other cytokines may provide at least a partial effect in pancytopenic patients with DC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163594     DOI: 10.1046/j.1365-2141.1997.622717.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita.

Authors:  Mohamad M Al-Rahawan; Neelam Giri; Blanche P Alter
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 2.  Cord blood transplantation for bone marrow failure syndromes: state of art.

Authors:  Simona Pagliuca; Annalisa Ruggeri; Régis Peffault de Latour
Journal:  Stem Cell Investig       Date:  2019-12-05

Review 3.  Treatment of inherited bone marrow failure syndromes beyond transplantation.

Authors:  Rodrigo T Calado; Diego V Clé
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Inherited bone marrow failure syndromes in 2012.

Authors:  Hirotoshi Sakaguchi; Koji Nakanishi; Seiji Kojima
Journal:  Int J Hematol       Date:  2012-12-28       Impact factor: 2.490

5.  [Dyskeratosis congenita in a 40-year-old patient].

Authors:  S Benoit; D Kraemer; E-B Bröcker; M Goebeler
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

Review 6.  Recent progress in dyskeratosis congenita.

Authors:  Nobuhiro Nishio; Seiji Kojima
Journal:  Int J Hematol       Date:  2010-10-01       Impact factor: 2.490

Review 7.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

8.  Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita.

Authors:  Blanche P Alter; Gabriela M Baerlocher; Sharon A Savage; Stephen J Chanock; Babette B Weksler; Judith P Willner; June A Peters; Neelam Giri; Peter M Lansdorp
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

9.  Dyskeratosis congenita.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.